Bioneer Corporation (064550.KQ)
KRW 19520.0
(-3.84%)
KRW 19520.0
(-3.84%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 80.61 Billion KRW | 46.04% |
| 2022 | 55.19 Billion KRW | 0.68% |
| 2021 | 54.82 Billion KRW | 26.9% |
| 2020 | 43.2 Billion KRW | -14.41% |
| 2019 | 50.48 Billion KRW | 58.89% |
| 2018 | 31.77 Billion KRW | 0.7% |
| 2017 | 31.54 Billion KRW | -43.34% |
| 2016 | 55.68 Billion KRW | 48.68% |
| 2015 | 37.45 Billion KRW | 0.8% |
| 2014 | 37.15 Billion KRW | -8.02% |
| 2013 | 40.39 Billion KRW | 10.05% |
| 2012 | 36.7 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 93.43 Billion KRW | 0.14% |
| 2024 Q1 | 93.3 Billion KRW | 15.75% |
| 2023 Q3 | 70.65 Billion KRW | 6.47% |
| 2023 Q4 | 80.61 Billion KRW | 14.1% |
| 2023 Q1 | 60.95 Billion KRW | 10.43% |
| 2023 FY | 80.61 Billion KRW | 46.04% |
| 2023 Q2 | 66.35 Billion KRW | 8.86% |
| 2022 Q3 | 53.03 Billion KRW | 2.4% |
| 2022 FY | 55.19 Billion KRW | 0.68% |
| 2022 Q4 | 55.19 Billion KRW | 4.08% |
| 2022 Q2 | 51.79 Billion KRW | -1.54% |
| 2022 Q1 | 52.6 Billion KRW | -4.06% |
| 2021 Q1 | 61.81 Billion KRW | 44.13% |
| 2021 Q4 | 54.82 Billion KRW | -32.57% |
| 2021 FY | 54.82 Billion KRW | 26.9% |
| 2021 Q3 | 81.31 Billion KRW | 6.27% |
| 2021 Q2 | 76.51 Billion KRW | 23.78% |
| 2020 FY | 43.2 Billion KRW | -14.41% |
| 2020 Q2 | 72.92 Billion KRW | -4.96% |
| 2020 Q3 | 110.43 Billion KRW | 51.43% |
| 2020 Q4 | 42.88 Billion KRW | -61.16% |
| 2020 Q1 | 76.72 Billion KRW | 51.99% |
| 2019 Q1 | 33.31 Billion KRW | 4.85% |
| 2019 Q2 | 33.85 Billion KRW | 1.63% |
| 2019 Q3 | 34.18 Billion KRW | 0.99% |
| 2019 FY | 50.48 Billion KRW | 58.89% |
| 2019 Q4 | 50.48 Billion KRW | 47.65% |
| 2018 Q1 | 31.7 Billion KRW | 0.5% |
| 2018 FY | 31.77 Billion KRW | 0.7% |
| 2018 Q4 | 31.77 Billion KRW | -35.95% |
| 2018 Q3 | 49.59 Billion KRW | -0.09% |
| 2018 Q2 | 49.64 Billion KRW | 56.58% |
| 2017 FY | 31.54 Billion KRW | -43.34% |
| 2017 Q4 | 31.54 Billion KRW | 2.31% |
| 2017 Q3 | 30.83 Billion KRW | -9.33% |
| 2017 Q2 | 34 Billion KRW | -11.01% |
| 2017 Q1 | 38.21 Billion KRW | 1.66% |
| 2016 Q2 | 38.71 Billion KRW | 4.44% |
| 2016 FY | 55.68 Billion KRW | 48.68% |
| 2016 Q3 | 38.26 Billion KRW | -1.15% |
| 2016 Q4 | 37.59 Billion KRW | -1.76% |
| 2016 Q1 | 37.06 Billion KRW | -1.03% |
| 2015 Q1 | 37.9 Billion KRW | 2.02% |
| 2015 Q4 | 37.45 Billion KRW | 3.06% |
| 2015 Q3 | 36.34 Billion KRW | -7.69% |
| 2015 Q2 | 39.36 Billion KRW | 3.85% |
| 2015 FY | 37.45 Billion KRW | 0.8% |
| 2014 Q2 | 40.26 Billion KRW | 5.08% |
| 2014 Q3 | 37.89 Billion KRW | -5.9% |
| 2014 Q4 | 37.15 Billion KRW | -1.94% |
| 2014 Q1 | 38.32 Billion KRW | -5.14% |
| 2014 FY | 37.15 Billion KRW | -8.02% |
| 2013 FY | 40.39 Billion KRW | 10.05% |
| 2013 Q4 | 40.39 Billion KRW | 8.57% |
| 2013 Q3 | 37.2 Billion KRW | -9.19% |
| 2013 Q2 | 40.97 Billion KRW | 9.24% |
| 2013 Q1 | 37.5 Billion KRW | 2.18% |
| 2012 FY | 36.7 Billion KRW | 0.0% |
| 2012 Q4 | 36.7 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| HLB Co., Ltd. | 169.47 Billion KRW | 52.435% |
| iNtRON Biotechnology, Inc. | 1.88 Billion KRW | -4186.964% |
| BINEX Co., Ltd. | 75.68 Billion KRW | -6.506% |
| Anterogen.Co.,Ltd. | 19.98 Billion KRW | -303.32% |
| MEDIPOST Co., Ltd. | 135.73 Billion KRW | 40.612% |
| CrystalGenomics, Inc. | 97.82 Billion USD | 17.595% |
| Helixmith Co., Ltd | 73.55 Billion KRW | -9.588% |
| Chabiotech Co.,Ltd. | 1069.23 Billion KRW | 92.461% |
| Medy-Tox Inc. | 137.14 Billion KRW | 41.221% |
| Peptron, Inc. | 16.36 Billion KRW | -392.459% |
| Amicogen, Inc. | 248.12 Billion KRW | 67.512% |
| Genexine, Inc. | 79.68 Billion KRW | -1.164% |
| HLB Therapeutics Co.,Ltd. | 29.27 Billion KRW | -175.347% |
| LegoChem Biosciences, Inc. | 41.28 Billion KRW | -95.273% |
| ALTEOGEN Inc. | 108.25 Billion KRW | 25.539% |
| PharmaResearch Co., Ltd. | 73.08 Billion KRW | -10.294% |
| SillaJen, Inc. | 19.4 Billion KRW | -315.498% |
| JETEMA, Co., Ltd. | 179.09 Billion KRW | 54.989% |
| OliX Pharmaceuticals,Inc | 52.48 Billion KRW | -53.576% |
| Genomictree Inc. | 7.81 Billion KRW | -931.845% |
| MedPacto, Inc. | 9.56 Billion KRW | -742.701% |
| D&D Pharmatech | 23.98 Billion KRW | -236.078% |
| EASY BIO,Inc. | 105.86 Billion KRW | 23.858% |
| GI Innovation, Inc. | 9.63 Billion KRW | -736.538% |